Holen Sie sich die Stockscreener-App
11.13
2.21%
0.16
Schlusskurs vom Vortag:
$10.97
Offen:
$10.99
24-Stunden-Volumen:
58,704
Relative Volume:
0.10
Marktkapitalisierung:
$695.15M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.71M
KGV:
-9.3255
EPS:
-1.1935
Netto-Cashflow:
$-54.12M
1W Leistung:
+6.88%
1M Leistung:
-10.52%
6M Leistung:
+19.66%
1J Leistung:
+194.28%
1-Tages-Spanne:
$10.99
$11.31
1-Wochen-Bereich:
$10.31
$11.56
52-Wochen-Spanne:
$3.33
$17.25
Design Therapeutics Inc Stock (DSGN) Company Profile
Firmenname
Design Therapeutics Inc
Sektor
Branche
Telefon
858-293-4900
Adresse
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
11.13 | 685.15M | 0 | -69.71M | -54.12M | -1.1935 |
VRTX
Vertex Pharmaceuticals Inc
|
435.62 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
640.47 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
800.86 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.89 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.09 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Eingeleitet | Jefferies | Buy |
| 2026-01-07 | Eingeleitet | Oppenheimer | Outperform |
| 2025-12-03 | Eingeleitet | Craig Hallum | Buy |
| 2025-12-03 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-11-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-05-04 | Hochstufung | Goldman | Sell → Neutral |
| 2022-06-10 | Eingeleitet | Wedbush | Outperform |
| 2022-05-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-19 | Eingeleitet | Goldman | Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-20 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Design Therapeutics Inc Aktie (DSGN) Neueste Nachrichten
Design Therapeutics (DSGN) Holds Steady Near Support as Consolidation PersistsVerified Analyst Reports - Newser
Design Therapeutics Inc. (DSGN) Q1 2026 Earnings: Narrower Loss Surpasses Expectations Amid Quiet QuarterGuidance Accuracy Score - Newser
Design Therapeutics (DSGN) price target increased by 17.05% to 17.51 - MSN
Design Therapeutics (DSGN) Edges Higher as Support Holds Above $10.60Social Trading Insights - Newser
Design Therapeutics Inc. (DSGN) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Progress in Gene Therapy PipelineRevenue Inflection Point - Newser
Analysts Conflicted on These Healthcare Names: Design Therapeutics (DSGN), Pro Medicus Limited (OtherPMCUF) and Boston Scientific (BSX) - The Globe and Mail
BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid - The Manila Times
DT-216P2 Shows Dose-Dependent Frataxin Increases and Clinical Improvements After 4 Weeks of IV Dosing in Friedreich Ataxia - Neurology Live
RBC Capital Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $20 - Moomoo
Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $22 - Moomoo
Design Therapeutics stock wobbles after rare genetic disease data - MSN
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich AtaxiaSlideshow (NASDAQ:DSGN) 2026-05-19 - Seeking Alpha
Nasdaq Down 200 Points; Brady Earnings Top Views - Sahm
Crude Oil Gains Over 2%; US Homebuilder Sentiment Increases In May - Sahm
Design Therapeutics (DSGN) Stock Forum and Discussion - Moomoo
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data - Sahm
Design Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20, Implies 39% Upside - TradingView
Design Therapeutics Down Over 25%, on Track for Largest Percent Decrease Since August 2023 -- Data Talk - Moomoo
RBC Capital raises Design Therapeutics price target on trial data By Investing.com - Investing.com Australia
Design Therapeutics Announces Biomarker and Clinical Data from Ongoing Phase 1/2 RESTORE-FA Trial of DT-216P2 in Friedreich Ataxia Patients - Minichart
Design Therapeutics reports positive trial data for FA treatment - Investing.com UK
Design Therapeutics reports positive trial data for FA treatment By Investing.com - Investing.com Australia
RBC Capital raises Design Therapeutics price target on trial data - Investing.com UK
DESIGN THERAPEUTICS, INC. (DSGN) - MSN
DSGN: DT-216P2 demonstrated strong biomarker and clinical improvements, supporting registrational plans - TradingView
Design Therapeutics Shares Jump on Encouraging Friedreich Ataxia Trial Results (DSGN) - Yahoo Finance
DSGN: DT-216 delivers rapid, significant frataxin increases and clinical benefit in FA patients - TradingView
Design Therapeutics reports Phase 1/2 trial data for DT-216P2 in Friedreich ataxia - Investing.com Nigeria
Design Therapeutics reports positive Phase 1/2 DT-216P2 data - TipRanks
Design Therapeutics' DT-216P2 Shows Clinical Improvements in Friedreich Ataxia Trial; Shares Rise Pre-Bell - marketscreener.com
Design Therapeutics stock surges on positive trial data By Investing.com - Investing.com South Africa
Design Therapeutics stock surges on positive trial data - Investing.com
RESTORE-FA data push Design Therapeutics (DSGN) to plan registrational path - Stock Titan
Design Therapeutics announces four-week IV data from the RESTORE-FA trial of DT-216P2 demonstrating clinical improvements and comprehensive biomarker activity in Friedreich Ataxia - marketscreener.com
DSGN: DT-216P2 showed dose-dependent clinical and biomarker improvements in Friedreich ataxia - TradingView
Design Therapeutics Announces Four-Week IV Data From The RESTORE-FA Trial Of DT-216P2 Demonstrating Clinical Improvements And Comprehensive Biomarker Activity In Friedreich Ataxia - TradingView
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia - The Manila Times
Jim Cramer: Design Therapeutics is 'pure spec,' buy this health care stock - MSN
User - The Chronicle-Journal
Design Therapeutics to present Phase 1/2 trial data for Friedreich’s ataxia drug DT-216P2 on May 18 - Pluang
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026 - The Manila Times
Design Therapeutics to Announce Phase 1/2 RESTORE-FA Trial Data for DT-216P2 in Friedreich's Ataxia on May 18, 2026 - Quiver Quantitative
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 ... - Caledonian Record
Friedreich’s ataxia trial data to be unveiled in May 18 webcast - Stock Titan
Jim Cramer on Design Therapeutics: “Pure Spec, Pure Spec” - Insider Monkey
Finanzdaten der Design Therapeutics Inc-Aktie (DSGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):